-
2026-526434-21-00
Bioequivalence
-
2026-526840-10-00
Not applicable (submitted trial is a BE study in health
-
2026-525780-41-00
Not applicable (submitted trial is a bioavailability tr 2026-06-22
-
2025-524219-35-00
treatment of myasthenia gravis 2026-06-15
-
2025-520618-76-00
ulcerative colitis 2026-06-12
-
2025-521329-34-00
Healthy volunteers, treatment for heart failure 2026-06-10
-
2025-525125-12-00
Migraine with or without aura 2026-05-05
-
2025-521384-12-00
obesity 2026-04-27
-
2025-522307-14-00
Melanoma 2026-01-19
-
2025-523736-39-00
No medical condition. 2025-12-29
-
2025-522680-14-00
Chronic Graft-versus-Host Disease 2025-12-23
-
2024-518285-27-00
Not applicable (submitted trial is a bioequivalence stu 2025-12-01
-
2024-518286-95-00
Not applicable (submitted trial is a bioequivalence stu 2025-07-02
-
2024-517298-26-00
adrenal insufficiency 2025-05-21
-
2024-513361-40-00
Arthrose digitale répondant aux critères de classificat 2024-12-05
-
2024-513729-22-01
metastatic prostate cancer 2022-02-01
-
2026-525752-29-00
bioavailability trial with healthy participants, therap 2026-06-01
-
2026-526040-13-00
No medical condition. 2026-05-25
-
2025-524311-37-00
chronic myeloid leukemia 2026-05-19
-
2026-525823-26-00
No medical condition. 2026-04-25
-
2026-525165-52-00
Growth hormone deficiency 2026-04-14
-
2024-516472-15-00
Type 1 diabetes mellitus (healthy participants) 2026-01-06
-
2025-520617-31-00
ulcerative colitis 2025-09-12
-
2023-509765-20-00
Melanoma: Adjuvant treatment of patients with Stage IIB 2024-10-21